Navigation Links
Soligenix Announces Grant of Broad European Patent for Topically Active Steroids to Treat Inflammatory Gastrointestinal Disorders
Date:5/10/2010

PRINCETON, N.J., May 10 /PRNewswire-FirstCall/ -- Soligenix, Inc. (OTC Bulletin Board: SNGX) (Soligenix or the Company), a late-stage biotechnology company, announced today that the European Patent Office granted patent EP 1392321 "Method of Treating Inflammatory Disorders of the Gastrointestinal Tract using Topically Active Corticosteroids."  The new patent's main claims cover the use of topically active corticosteroids in orally administered dosage forms that act concurrently in the upper and lower gastrointestinal tract. These dosage forms include orBec®, an oral formulation of beclomethasone dipropionate (BDP), a topically active corticosteroid, currently in a confirmatory Phase 3 clinical trial for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD), an inflammatory condition arising from hematopoietic stem cell transplantation.  

"The granting of the European patent strengthens our intellectual property portfolio in the field of topically active steroids.  It demonstrates the novelty and utility of our approach to treating inflammatory GI diseases, such as GI GVHD with our two-pill system comprising an immediate- release and a delayed-release combination of oral BDP," said Christopher J. Schaber, PhD, President and CEO of Soligenix.  "This is the first European patent in our portfolio that addresses topically active formulations of corticosteroids, and we expect additional patents will be granted in the near future.  We believe that our oral BDP formulations may also have utility in other inflammatory GI diseases, such as radiation enteritis, irritable bowel syndrome and Crohn's disease."

In addition to issued patents and pending worldwide patent applications held by or exclusively licensed to Soligenix, orBec® also benefits from
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. DOR BioPharma Announces Corporate Name Change to Soligenix and Begins Trading Under New Ticker Symbol SNGX
2. Soligenix Appoints Robert J. Rubin, MD, to its Board of Directors
3. Soligenix to Present at 8th Annual BIO Investor Forum
4. Soligenix to Present at 12th Annual BIO CEO & Investor Conference
5. Soligenix Reports Third Quarter 2009 Financial Results
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
8. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
9. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
10. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
11. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014  Next month, executives from clinical trial marketing firm ... beginning with Patient-Centered Clinical Trials 2014 , to be ... , September 4-5. Patient recruitment experts Bonnie A. ... will share insights on the benefits of employing an ... – from media to mobile apps – can be used ...
(Date:8/28/2014)... , Aug. 28, 2014  Armetheon, Inc. ( ... novel mid- to late-stage cardiovascular drug candidates, today ... its first round of financing. The Series A ... Hercules Bioventures with participation from investors that included ... executive, Dr. Larry Hsu , the founder ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 A ... around the world is available from Strategic Consulting, ... companies. “ Industrial Microbiology Market Review, Fourth Edition: ... Market ” (IMMR—4) tracks and compares microbiology test ... North America, Europe and Asia, and forecasts future ...
(Date:8/28/2014)... CA (PRWEB) August 28, 2014 ... is offering a promotion for Eppendorf Safe ... customers to purchase the highest quality tubes at ... are ideal for customers doing chemical, medical, pharmaceutical, ... technicians who are not regularly able to afford ...
Breaking Biology Technology:BBK Worldwide Leads Sessions at Key September Events 2Armetheon Completes $7.0 Million Series A Financing 2Armetheon Completes $7.0 Million Series A Financing 32 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3
... EDMONTON, April 22 /PRNewswire-FirstCall/ - Quest PharmaTech ... announce that it will receive,generous support from ... (SDT) for oncology applications., Sonodynamic Therapy ... in,Hypocrellin-based photodynamic therapy for oncology and skin ...
... $250,000 under March ... ... BMRX), a leading developer and supplier of consumer-based,finger-activated products, today announced ... personnel of Sequiam,Corporation (OTC Bulletin Board: SQUME) through a previously announced,agreement ...
... Conn., April 22 Rib-X Pharmaceuticals, Inc.,("Rib-X" ... on the,discovery and development of novel antibiotics ... that Graham Johnson,Ph.D., Chief Research Officer and ... Cambridge Healthtech Institute,s 2nd Annual "The,Challenge of ...
Cached Biology Technology:Quest PharmaTech Receives Support from National Research Council's Industrial Research Assistance Program (NRC-IRAP) to develop Ultrasound Technology for the Treatment of Cancer 2bioMETRX, Inc. Initiates Integration of Personnel and Assets of Sequiam Corp. 2Rib-X Pharmaceuticals to Present at Cambridge Healthtech Institute's 2nd Annual Challenge of Antibacterial Development Conference 2
(Date:8/29/2014)... type and number of connections in transcription factor networks ... in a study published in PLOS Computational Biology ... assortativity signature contributes to a network,s resilience against mutations. ... out-out assortativity of TFN models has a greater effect ... types of assortativity," said Dov A. Pechenick, PhD, lead ...
(Date:8/29/2014)... twist them, fold them: modern materials that are light, ... as artificial skin or electronic paper. , Making such ... but a new way of working with copper nanowires ... , Previous success in the field of ultra-lightweight ... precious gold and silver nanowires. , By turning ...
(Date:8/28/2014)... an expansion of marine protected areas is needed to ... According to investigators from the Wildlife Conservation Society and ... on saving the largest numbers of species, often at ... difficult-to-replace ecological functions. , Many vital ecological ... that also are food for millions of people. ...
Breaking Biology News(10 mins):Assortativity signatures of transcription factor networks contribute to robustness 2Copper shines as flexible conductor 2Study finds marine protected areas inadequate for protecting fish and ocean ecology 2
... EUGENE, Ore. -- Using new optical equipment, a ... of virtual reality, monitored both their behavior and brain ... brain operates as it moves. The new research ... Scientific Instrumentation Inc. (ASI) -- should help neuroscientists around ...
... largest celebration of science and engineering, the USA ... D.C., April 28-29, 2012. For the second year, ... hands-on experiments. At Carnegie,s booth last year, visitors ... produced by our high pressure lab, touched the ...
... organisms, germ cells give rise to gametes and serve ... germ cell development is the decision to leave mitosis ... eggs and sperm. Germ cell development involves unique gene ... ensure success during fertilization and embryo development. Written ...
Cached Biology News:Worm-tracking challenge leads to new tool for brain research 2Worm-tracking challenge leads to new tool for brain research 3Carnegie partners with USA Science & Engineering Festival for second year 2Carnegie partners with USA Science & Engineering Festival for second year 3
TGF-beta 1,-2,-3 MAb (Clone 1D11)...
Request Info...
Mouse monoclonal [B314.1 (MAC 387)] to Macrophage L1 protein Calprotectin (rating: ****) ( Abpromise for all tested applications)....
Human/Mouse/Rat AMPK beta 1 Affinity Purified Polyclonal Ab...
Biology Products: